Alexandria Venture Investments

Alexandria Venture Investments is a strategic venture capital arm of Alexandria Real Estate Equities. Alexandria Venture Investments provides long-term strategic investment capital to innovative life science and technology entities developing breakthrough technologies and therapies. Leveraging their experience and in-depth understanding of the life science and technology industries, their long-term relationships with leading investors, and their world-class scientific advisory network, they are uniquely positioned to fund seed-, early-, and growth-stage companies.

Thomas Andrews

Co-President and Regional Market Director

JC

John Cox

SVP - Regional Market Director

JH

John H. Cunningham

EVP - Regional Market Director

LD

Larry Diamond

Co-COO and Regional Market Director

Joel Marcus

Head of Alexandria Venture Investments

TM

Todd Miller

SVP -Regional Leasing and Asset Services

DJ

Daniel J. Ryan

Co-CIO

OS

Oliver Sherrill

SVP - Regional Market Director

202 past transactions

Vtesse, Inc.

Series A in 2016
Vtesse, Inc. develops drugs for patients suffering from rare diseases. The company focuses on conducting the clinical study of VTS-270 for the treatment of Niemann-Pick disease type C (NPC), as well as on conducting pre-clinical discovery and development of other novel drugs for NPC and other lysosomal storage diseases. Vtesse, Inc. is based in Gaithersburg, Maryland. As of April 3, 2017, Vtesse, Inc. operates as a subsidiary of Sucampo Pharmaceuticals, Inc.

Vigil Neuroscience

Series A in 2020
Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.

LQT Therapeutics, Inc

Series A in 2021
Long QT Syndrome (LQTS) is a genetic disorder that causes a prolongation between the beginning of the QRS complex and the end of the T waveQ and T waves on the EKG, indicating a prolongation of ventricular repolarization and the action potential duration. The lengthening of this complex is associated with unexpected and life threatening ventricular arrhythmias. Click below to learn more about our programs.

Wugen

Series B in 2021
Wugen is a developer of a novel CAR-T therapy platform intended for T-Cell Malignancies.The company's state-of-the-art gene editing technologies and cutting-edge Car-T cell therapy address some of the challenges that have limited the clinical development of allogeneic Car-T cells, enabling patients aid in the treatment of cancer.

IgGenix

Series B in 2023
IgGenix, Inc, a biotechnology company, develops an antibody therapeutics platform for the treatment of food and non-food allergies, and other severe allergic conditions. It isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and prevent the allergic cascade. The company captures and analyzes very rare human B cells that express allergen-binding antibodies, and engineers them with immune modulating activities derived from the IgG antibody class to suppress allergic reactions. The company was incorporated in 2019 and is based in South San Francisco, California.

Garuda Therapeutics

Series B in 2023
Garuda Therapeutics is developing off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases.

TwinStrand Biosciences

Series B in 2021
TwinStrand Biosciences, Inc. develops and commercializes Duplex Sequencing that allows levels of accuracy and sensitivity. The company’s Duplex Sequencing improves the accuracy of DNA sequencing by various folds and allows detection of mutations that are invisible by other approaches. Its technology has applications in a range of fields, including oncology, infectious disease, organ transplantation, reproductive and genetic health, and forensics. The company was incorporated in 2015 and is headquartered in Bellevue, Washington.

Nohla Therapeutics

Series B in 2018
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.

Dren Bio

Series B in 2022
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.

Nitrome Biosciences, Inc.

Series A in 2021
Nitrome Biosciences, Inc. provides a platform to discover and identify drugs against newly identified class of enzymes. The company targets Parkinson’s disease and develops cures for various aging-dependent diseases, including neurodegenerative, Type II diabetes, heart, and cancer diseases. Nitrome Biosciences, Inc. was formerly known as Nitrome, Inc. The company was incorporated in 2012 and is headquartered in Jackson, Wyoming. It has sites in Jackson, Wyoming; and San Francisco, California.

Ambys Medicines

Series A in 2021
Ambys Medicines is working to fundamentally transform the lives of people suffering from severe liver diseases by creating breakthrough therapies capable of restoring liver function, preventing the progression of liver disease, and treating the devastating complications of liver failure.

Encodia, Inc.

Series C in 2020
Encodia, Inc. engages in proteomics research and creates scalable and parallelized approaches to protein analysis. The company was founded in 2015 and is based in San Diego, California.

Disc Medicine, Inc.

Series B in 2021
Disc Medicine is led by an experienced team of scientists and industry experts, and supported by a panel of advisors with a strong track record of discovering and developing new and innovative therapies. Disc Medicine was founded by Atlas Venture and Brian MacDonald, with Novo Ventures and Access Biotechnology joining as additional investors.

Asher Bio

Series B in 2021
Asher Bio is an information technology company that specializes in the fields of CFO Office transformation, profitability, and cost management. It focuses on building and developing better immunotherapy for cancer. The company was founded in 2019 and headquartered in San Francisco, California.

Gavilán Biodesign

Series A in 2023
Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Meiogenix SAS

Series A in 2021
Meiogenix SAS operates as a biotech company that develops breeding and genomic technologies. It offers SpiX technology, which modulates the process of homologous recombination in the genome by increasing its frequency in cold regions and PhoeniX, which is a non-GM method that induces meiotic recombination in hybrid diploid (or polyploid) yeast cells without the need to go through the entire process of meiosis. The company helps to develop new products to address global food and industrial challenges. The company was incorporated in 2010 and is based in Paris, France.

MOMA Therapeutics

Series A in 2020
MoMa Therapeutics, Inc. discovers precision medicines by targeting the molecular machines that underlie human disease. MoMa Therapeutics, Inc. was formerly known as ATPases NewCo, Inc. and changed its name to MoMa Therapeutics, Inc. in March 2020. The company was founded in 2019 and is based in Cambridge, Massachusetts.

Affinia Therapeutics

Series A in 2020
Affinia Therapeutics is a developer of a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies intended to develop medicines for devastating diseases. The company leverages synthetic and systems biology combined with high-throughput screening and tissue and single-cell resolution for people affected by muscle and central nervous system (CNS) diseases with significant unmet needs, thereby providing medical professionals with the rational design of novel vectors and gene therapies with remarkably improved properties.

IpiNovyx Bio

Seed Round in 2021
IpiNovyx Bio is a biopharmaceutical company developing a platform of best-in-class immunoproteasome modulating therapeutics to transform the treatment of autoimmune and inflammatory diseases.

Myeloid Therapeutics

Series A in 2023
Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyte approach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners.

Kallyope

Series A in 2015
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology

Quentis Therapeutics

Series A in 2018
Quentis Therapeutics is a developer of immuno-therapeutics designed to address ER stress in multiple diseases. The company's therapeutics are designed to target ER stress pathways and awaken the immune system's ability to fight cancer, enabling patients to get access to new treatments for cancer.

Element Biosciences, Inc.

Series B in 2020
Element Biosciences, Inc. develops genetic analysis tools for the research and diagnostic markets. The company provides a disruptive DNA sequencing technology and a sequencing platform, such as surface chemistry, sequencing chemistry, detection, and data analysis. The company was incorporated in 2017 and is based in San Diego, California.

Terray Therapeutics

Series A in 2022
Terray Therapeutics, Inc. operates as a biotechnology company. The company develops treatments for intractable cause of human diseases. It engages in development of a screening platform for drug discovery and Platinum Technology, which is working on an electrode-like product for deep brain stimulation. The company was founded in 2018 and is based in Pasadena, California.

Harpe Bio

Series A in 2022
Harpe Bioherbicide Solutions is a Raleigh-based company that provides sustainable weed-management solutions for organic and industrial agriculture. The company was founded in 2020 by Chad Brommer and is headquartered in Raleigh, North Carolina, United States.

Veralox Therapeutics

Series A in 2021
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.

Fountain Therapeutics

Series A in 2021
Fountain Therapeutics is discovering and developing treatments for aging-associated diseases. Fountain Therapeutics was founded with the belief that a future in which we live healthier lives longer is more desirable than one in which the company continues to be afflicted by the disease of aging. The company builds a transformative model of aging that re-creates many of the complex hallmark features of aging but in a laboratory dish. We are combining this powerful cellular model with the latest in artificial intelligence and computer vision to develop a disruptive unbiased platform for the identification of novel targets and potential therapeutics.

Antiva Biosciences, Inc.

Series C in 2017
Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco.

Insitro

Series A in 2018
Insitro is a operator of a data-driven drug discovery and development company that uses machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company uses state-of-the-art technologies from Bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via a novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.

Eclipse Bioinnovations

Series A in 2022
Eclipse Bioinnovations is an RNA Next-Generation-Sequencing company founded in 2017 based on technology developed in Professor Gene Yeo’s laboratory at UC San Diego. Their mission is to use their first-in-class Eclipse-Seq RNA NGS platform technologies to accelerate the creation and development of truly safe and effective RNA medicines. Eclipse’s founders developed eCLIP, the world’s most efficient and unique CLIP-seq technology for identifying RNA binding protein gene partners and gene maps. Eclipse’s eCLIP is offered as a service and kit for biopharma companies and academic researchers, and can be customized for different RNAs such as siRNA or miRNA.

Acrigen Biosciences

Seed Round in 2021
Acrigen Biosciences is dedicated to making gene editing safe. It develops technologies to improve efficiency and enhance the safety of CRISPR-Cas based gene editing. CRISPR-Cas system which enables the precise enzymatic editing of genes is one of the most exciting and promising techniques to be developed in the last few years with the capability to prevent or cure many devastating diseases. It was founded in 2019 and is headquartered in Berkeley, California.

Rheostat Therapeutics

Series A in 2018
Rheostat’s mission is to invent novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy. They believe that the degradation of toxic cellular components, whether they are damaged organelles or aggregated proteins, is a fundamental node of biology. Mutations that impair these clearance pathways cause multiple neurodegenerative diseases, many of which are associated with cognitive impairment. They aim to leverage our understanding of these critical pathways to discover and develop novel small molecules that will restore cellular balance and treat neurodegenerative and rare diseases.

Insitro

Series A in 2019
Insitro is a operator of a data-driven drug discovery and development company that uses machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company uses state-of-the-art technologies from Bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via a novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.

Antiva Biosciences, Inc.

Series C in 2018
Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco.

Bright Peak Therapeutics

Series B in 2021
Bright Peak Therapeutics is a biotechnology company with a platform capable of chemically synthesizing and optimizing natural proteins such as cytokines.

Remix Therapeutics

Series B in 2022
Remix Therapeutics Inc. engages in the biotech research and development business. It discovers and develops various novel therapeutic RNA processing modulators to target various undruggable disease drivers. The company also offers biology platform to identify and prioritize targets with therapeutically-tractable intervention points in RNA processing. Its REMseq platform validates targets and chemical matter discovery and optimization. The company was founded in 2018 and is based in Cambridge, Massachusetts.

ROME Therapeutics, Inc.

Series B in 2021
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.

Codiak BioSciences, Inc.

Series B in 2016
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Neurona Therapeutics Inc.

Venture Round in 2021
Neurona Therapeutics Inc. develops cell-based therapies for the treatment of neurological disorders. The company develop therapeutic compositions of specific nerve cells for targeted delivery into the injured nervous system. The company was incorporated in 2008 and is based in South San Francisco, California.

Korro Bio

Series A in 2020
Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms. Korro Bio was created to lead the field of RNA editing. The company is advancing a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. In 2018,

Invaio Sciences

Series C in 2021
Invaio Sciences, Inc. is a Flagship Pioneering Company startup in Cambridge. They are at the forefront of developing novel technologies based on groundbreaking science with an intent to positively impact their planet by enabling the application of breakthrough solutions in agriculture, human health, animal nutrition and animal health.

Avelas Biosciences

Series C in 2016
Avelas BioSciences, Inc. is a clinical stage biotechnology company that focuses on developing technologies that advance care for cancer surgery and therapeutic intervention. It develops AVB-620, an intravenously administered in vivo fluorescent protease-activatable peptide that detects, marks, and diagnoses cancer. The company was incorporated in 2008 and is based in La Jolla, California.

Boragen

Series A in 2017
Boragen develops synthetic chemistry platforms designed to produce next-generation fungicides. The platform supports sustainable farming methods by creating a compound that decreases the probability of fungicide resistance and reduces the amount of chemical applied while maintaining performance and efficacy. The company utilizes boron’s unique properties to design and develop novel solutions targeting needs in crop protection, animal health, and human health. Founded in 2015, Boragen is based in Durham, North Carolina.

Atara Biotherapeutics

Series B in 2013
Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com.

Kytopen Corp.

Series A in 2021
Kytopen is a developer of a cell therapy platform designed for non-viral delivery of molecules into hard-to-transfect immune cells. The company's technology combines microfluidics and automation to make non-viral delivery of molecules easier, faster and cheaper through an automated cell engineering platform, enabling researchers to find new discoveries in biology that will lead to cost effective cell and gene therapies.

Aspen Neuroscience

Seed Round in 2019
Aspen Neuroscience, Inc. develops induced pluripotent stem cells to treat neurological conditions. Its products pipeline includes ANPD001, an autologous neuron replacement therapy in sporadic Parkinson disease; and ANPD002, a gene-edited autologous neuron replacement therapy for familial forms of Parkinson disease. The company was incorporated in 2018 and is based in San Diego, California.

Shenandoah Growers

Venture Round in 2021
Shenandoah Growers is a grower, packer, and shipper of fresh organic culinary herbs. The company provides a 365-day supply of fresh, organic herbs to grocery stores, so millions of consumers can now eat locally all year. Their products are healthy, delicious, and aimed at making the world a lot more flavorful.

TwinStrand Biosciences

Series A in 2020
TwinStrand Biosciences, Inc. develops and commercializes Duplex Sequencing that allows levels of accuracy and sensitivity. The company’s Duplex Sequencing improves the accuracy of DNA sequencing by various folds and allows detection of mutations that are invisible by other approaches. Its technology has applications in a range of fields, including oncology, infectious disease, organ transplantation, reproductive and genetic health, and forensics. The company was incorporated in 2015 and is headquartered in Bellevue, Washington.
Compass Therapeutics is a clinical-stage biotechnology company targeting the human immune synapse with a new generation of antibody therapeutics. Compass has broadly drugged the immune system by generating epitopically diverse antibody panels to more than 40 targets across all immune cell types and is leveraging its proprietary StitchMabs and common light-chain based multispecific platforms to empirically identify combinations and multispecific with optimized activity. The company’s lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, which is in a Phase 1 study in patients with inadequate responses to PD-1/PD-L1 checkpoint inhibitors. Compass is also progressing several preclinical assets including a novel class of NK cell engagers targeting NKp30 and multiple bispecific checkpoint programs. The company’s offices and labs are based in Kendall Square in Cambridge, Mass.

Crop Enhancement

Convertible Note in 2021
Crop Enhancement LLC, an early stage specialty materials company, develops anchoring and controlled-release formulation technologies for agricultural chemicals. The company’s formulation technologies enable release of chemical agents, such as pesticides, herbicides, and fertilizers into target microenvironments. Crop Enhancement LLC was founded in 2011 and is based in San Jose, California.

Alloy Therapeutics

Series C in 2021
Alloy Therapeutics makes medicine by democratizing access to foundational drug discovery platforms and services. Alloy-Gx, its first platform, is a royalty-free suite of immunocompetent transgenic mice enabling best-in-class in vivo human antibody discovery. Founded in 2017, Alloy Therapeutics is headquartered in Lexington, Massachusetts.

GeneCentric Diagnostics

Series B in 2021
GeneCentric Diagnostics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company was incorporated in 2011 and is based in Durham, North Carolina.

Molecular Assemblies

Series A in 2021
Molecular Assemblies, Inc. develops an enzymatic DNA synthesis technology for DNA-based products. Its technology enables the reading and writing of DNA for various industries. The company serves life sciences, industrial, information storage, nanotechnology, and DNA electronics markets. Molecular Assemblies, Inc. was founded in 2013 and is based in San Diego, California.

Parthenon Therapeutics

Series A in 2021
Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.

ImmuneID

Series A in 2021
ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases.

ImmunAI

Series B in 2021
Immunai's mission is to map the entire immune system and its functions using single-cell genomics and machine learning. Immunai leverages single-cell technologies to profile cells from a blood sample, and uses machine-learning algorithms (powered by its proprietary database) to map the hundreds of cell types and their states to create an immune profile. They work on biomarker discovery and insights that identify how a cell responds to its changing environment. The company is located in New York City, San Francisco, and Tel Aviv, Israel.

Lycia Therapeutics

Series B in 2021
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA.

miRecule

Venture Round in 2021
MiRecule is an early-stage biotechnology company that focuses on developing microRNA-based therapeutics. It features a genomic-based drug development platform that integrates genomic sequencing, expression, and prognostic data from cancer patients. The company was founded in 2016 and headquartered in Gaithersburg, United States.

Deep Genomics Inc.

Series C in 2021
Deep Genomics Inc., an artificial intelligence (AI) therapeutics company, develops individualized genetic medicines by creating AI systems that are used to accelerate various steps of drug discovery and development, including target discovery, lead optimization, toxicity assessment, and innovative trial design. It develops and markets therapies for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company develops oligonucleotide therapies that target the genetic determinants of disease at the level of RNA or DNA. Deep Genomics Inc. was founded in 2014 and is based in Toronto, Canada.

Deka Biosciences

Series A in 2021
Early stage biotechnology start-up developing next generation cytokine therapeutics

IgGenix

Series A in 2021
IgGenix, Inc, a biotechnology company, develops an antibody therapeutics platform for the treatment of food and non-food allergies, and other severe allergic conditions. It isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and prevent the allergic cascade. The company captures and analyzes very rare human B cells that express allergen-binding antibodies, and engineers them with immune modulating activities derived from the IgG antibody class to suppress allergic reactions. The company was incorporated in 2019 and is based in South San Francisco, California.

Ozette Technologies

Series A in 2022
Ozette is a life sciences data startup company that develops an artificial intelligence-enabled immune monitoring platform. It empowers scientists to quickly extract reliable insights from single-cell data across instruments, experiments, and disease states, with a focus on cancer patients. The data can be used by doctors to diagnose and prescribe medication with greater accuracy. In 2020, co-founders Raphael Gottardo, Greg Finak, Ali Ansary, and Evan Greene headquartered the life science company in Seattle, Washington.

GNS Healthcare

Series D in 2019
GNS Healthcare is a big data analytics company that focuses on discovering what works in the healthcare industry and for whom. They focus on advancing and applying industrial-scale data analytics to empower key healthcare stakeholders to solve complex care, treatment, and cost challenges. It was founded in 2000 and headquartered in Cambridge, Massachusetts.

Tavros Therapeutics

Seed Round in 2022
Tavros Therapeutics is an emerging biotechnology company that discovers and develops therapies for cancer. The company was founded in 2019 and based in Durham, North Carolina.

Senda Biosciences

Series B in 2021
Senda Biosciences is pioneering the field of Intersystems Biology to create novel treatments for human disease. Intersystems Biology focuses on how molecular connections between botanical, bacterial, and human cells—coevolved over millennia—define health and disease. Senda's Intersytems Biology discovery platform, built using new techniques in machine learning and computational biology, has been able to generate novel, actionable insights into the trillions of interspecies molecular connections in the human body, and harnesses the power of this "pharmacy within us" with novel pharmacological approaches. The power of the Senda platform is illustrated by six preclinical programs in oncology, neurology, chronic disease, and metabolic disease.

Tara Biosystems

Series A in 2020
Tara Biosystems provides predictive, in vitro human cardiac tissue models for use in drug discovery, safety assessment and translational medicine. Tara Biosystems offers a high-fidelity solution that is based on human stem cell-derived cardiac tissue matured to physiologically relevant adult-like levels and provides direct measures of cardiac functionality, including contractile force. The company is dedicated to pioneering predictive cardiac tissue models that enable the faster, safer, and more reliable development of new medicines.

Kojin Therapeutics

Series A in 2021
Founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, Kojin is accelerating a drug discovery platform that connects complex cell states to known biochemical processes such as ferroptosis, or iron-dependent cell death, and enables the development of selective therapies for a broad range of hard-to-treat diseases. The company’s investors include Polaris Partners, Newpath Partners, Cathay Health, Leaps by Bayer, AbbVie Inc., Eventide Asset Management, Alexandria, and the Dana-Farber Cancer Institute venture firm, Binney Street Capital.

Inari Inc

Series D in 2021
Inari Agriculture, Inc. develops customized seeds to grow crop using CRISPR gene editing technology. The technology helps crops grow in local conditions such as humidity, temperatures, and soil types. The company uses the technology on seeds such as wheat, soya bean, and corn. Inari Agriculture, Inc. was formerly known as VL40, Inc. The company was incorporated in 2016 and is based in Cambridge, Massachusetts.
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.

Ventus Therapeutics

Series B in 2021
Ventus Therapeutics U.S., Inc., a biopharmaceutical company, develops novel therapeutics that target the innate immune system to treat autoimmune diseases, inflammatory diseases, and cancer. It offers structural immunology platform that employs protein engineering to solve molecular structures, enable novel binding and functional screening assays, and power structure-based modeling. The company develops small-molecule medicines to target proteins in the inflammasome and nucleic acid sensing signaling pathways. The company was incorporated in 2019 and is based in Natick, Massachusetts. It has an additional location in Montreal, Canada.

Avalo

Convertible Note in 2022
Avalo is a biotech company generating crop resilience through gene discovery and control for a healthier and fuller world. The company uses interpretable machine learning to identify genes in plants at a much faster pace to help develop better crops.
eFFECTOR Therapeutics is an early stage company focused on the discovery and development of new small molecule cancer therapeutics. eFFECTOR is developing translation regulators to selectively block disregulated translation impacting tumor growth and survival. The company has selected control of mRNA translation as a key point of theerapeutic intervention, providing potency and selectivity while inhibiting growth of cancer cells. eFFECTOR's novel approach provides a real opportunity to bring innovative new medicines to patients in need.

Humacyte

Post in 2021
Humacyte, Inc., a medical research, discovery, and development company, focuses on developing and commercializing a proprietary technology based on human tissue-based products for application in regenerative medicine and vascular surgery. It designs acellular extracellular matrices, which are formed in vitro from banked vascular smooth muscle cells and decellularized to eliminate the risk of rejection; and used as tissue-engineered grafts for patients in need of vascular repair or replacement. The company was incorporated in 2004 and is headquartered in Morrisville, North Carolina.
Soteria is developing a next generation of conditionally active bispecific t-cell engaging antibodies to treat cancer patients with solid tumors. Soteria’s highly innovative T-LITE™ platform provides small molecule-dependent activation of bispecific antibody therapies, enabling safer and more efficacious treatments through pulsatile activity, reduced side effects and higher dosing.

SeQure DX

Venture Round in 2021
SeQure DX is in the business activities at non-commercial site business. It was founded in 2020 and is based in Waltham, Massachusetts.

Sonoma Pharmaceuticals

Series A in 2020
Sonoma Pharmaceuticals is a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 33 countries. The company’s products, over 100 SKUs commercialized worldwide, are used to treat patients in advanced wound management, dermatology, women’s health and animal health; addressing the unmet medical needs of these markets—while raising the standard of patient care and lowering overall healthcare costs.
Advanced Animal Diagnostics, Inc. commercializes proprietary technology for the diagnosis of farm-animal diseases. It uses an animal's own immune response to detect and stage infections to improve the quality of life for producers, processors, animals, and consumers. The company offers QuickSmear, a rapid differential slide to speed and simplify production animal research using differential cell counts; and SCC+ System for early detection of mastitis. Advanced Animal Diagnostics was founded in 2001 and is based in Durham, North Carolina.

Skyhawk Therapeutics, Inc.

Venture Round in 2018
Skyhawk Therapeutics is a provvider of small molecule therapeutics designed to offer therapies that correct RNA expression.The company's therapeutics use proprietary technology that helps the rational design of small molecules that target specific binding pocket regions on RNA, using both sequence and structural specificity, at particular moments in the RNA splicing process, enabling physicians to target diseases driven by a type of RNA mis-splicing called exon skipping.

Molecular Assemblies

Series A in 2019
Molecular Assemblies, Inc. develops an enzymatic DNA synthesis technology for DNA-based products. Its technology enables the reading and writing of DNA for various industries. The company serves life sciences, industrial, information storage, nanotechnology, and DNA electronics markets. Molecular Assemblies, Inc. was founded in 2013 and is based in San Diego, California.

Tiburio Therapeutics

Series A in 2019
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.The company's compounds aid in the treatment of non-functioning pituitary adenoma using a dopamine-somatostatin chimeric molecule that has the potential to shrink or halt tumor growth, providing patients with effective treatment for rare neuroendocrine tumors and endocrine diseases.
Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. It was founded in 2015 and headquartered in Woburn, Massachusetts.

ImCheck Therapeutics SAS

Series B in 2019
ImCheck Therapeutics SAS develops immunotherapeutics for patients with severe unmet medical needs. The company primarily focuses on immuno-oncology. It develops immunotherapy antibodies, which include immunomodulators and butyrophilins to treat a range of autoimmune diseases. The company was founded in 2015 and is based in Marseille, France.

ApoGen Biotechnologies

Series A in 2016
ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapies eventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.

Stoke Therapeutics, Inc.

Series B in 2018
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.

Lodo Therapeutics

Series A in 2016
Lodo Therapeutics Corporation is a drug discovery and development company focused on the creation of naturally derived novel therapeutics that will have a dramatic impact human health on a global basis. Lodo seeks to work in partnership with global pharmaceutical companies and world leading Non-Governmental Organizations (NGO’s) to tackle some of the greatest challenges in human health: resistant infectious disease and cancers. Lodo Therapeutics was created to pursue the scientific vision of Dr. Sean Brady at Rockefeller University. Dr. Brady and his laboratory have developed a genome-based, culture-independent platform for the discovery, biosynthesis, and characterization of small molecules from microbial sources present in soil samples. Lodo believes that the potential cures for a number of deadly and/or debilitating diseases literally lie at our feet. By combining the advancements in DNA sequencing and bioinformatics, this innovative discovery platform exploits the power of microbial evolution for the identification of therapeutically valuable pharmaceutical products derived from natural sources. Lodo Therapeutics, an Accelerator Corporation-backed entity, is headquartered in New York City. The company’s lab and offices are located in the Alexandria Center for Life Science, New York City’s first and only premier life science park.

eGenesis

Series A in 2017
Egenesis Inc., a biotechnology company, operates as a gene editing and genome engineering that develops human transplantable organs, tissues, and cells. It offers a gene editing platform for developing human compatible organs. The company also provides development, such as gene engineering, single cell cloning, somatic cell nuclear/embryo transfer, organ procurement, and transplantation. The company was incorporated in 2015 and is based in Cambridge, Massachusetts with an additional office in New York, New York.

Aura Biosciences, Inc.

Series C in 2017
Aura Biosciences, Inc., a biotechnology company, develops a class of therapies to target and destroy cancer cells using viral nano-particle conjugates. The company develops AU-011 that includes viral nanoparticles, modeled on the human papillomavirus (HPV), conjugated to infrared-activated small molecules. The company’s AU-011 is used for the treatment of ocular (uveal) melanoma, which is a primary cancer of the eye. The company was incorporated in 2009 and is based in Cambridge, Massachusetts.